Table 1.
Patient, Transplant and Pathologic Characteristics
| Overall N = 182 |
Adherent N = 111 |
Non-adherent N = 71 |
p value | |
|---|---|---|---|---|
| Age, years | 40.2 ± 13.0 | 42.4 ± 12.9 | 36.7 ± 12.5 | 0.003 |
| Male | 107 (59) | 72 (65) | 35 (49) | 0.04 |
| Race/Ethnicity | ||||
| • White | 87 (48) | 58 (52) | 29 (41) | 0.06 |
| • Black | 91 (50) | 49 (44) | 42 (59) | |
| • Hispanic | 4 (2) | 4 (4) | 0 (0) | |
| Living Donor | 78 (43) | 50 (45) | 28 (39) | 0.53 |
| Cause of ESRDa | ||||
| • HTNb | 34 (19) | 19 (17) | 15 (21) | 0.10 |
| • DMc | 40 (22) | 31 (28) | 9 (13) | |
| • GNd | 59 (32) | 34 (31) | 25 (35) | |
| • PKDe | 7 (4) | 6 (5) | 1 (1) | |
| • Other | 29 (16) | 14 (13) | 15 (21) | |
| • Unknown | 13 (7) | 7 (6) | 6 (9) | |
| Maintenance ISf | ||||
| • FKg/MMFh/Pred | 101 (55) | 60 (54) | 41 (58) | 0.12 |
| • FK/MMF | 31 (17) | 14 (13) | 17 (24) | |
| • CsAi/MMF/Pred | 22 (12) | 17 (15) | 5 (7) | |
| • MToRj-based | 14 (8) | 11 (10) | 3 (4) | |
| • Other | 14 (8) | 9 (8) | 5 (7) | |
| Steroid withdrawal | 33 (18) | 13 (12) | 20 (28) | 0.005 |
| Nadir baseline SCrk, mg/dL | 1.52 ± 1.19 | 1.73 ± 1.45 | 1.19 ± 0.45 | 0.002 |
| Index eGFRl, mL/min/1.73m2 | ||||
| • > 30 | 34 (19) | 24 (22) | 10 (14) | 0.13 |
| • 11–30 | 91 (50) | 58 (52) | 33 (46) | |
| • ≤ 10 | 57 (31) | 29 (26) | 28 (40) | |
| Need for dialysis on presentation | 34 (19) | 18 (16) | 16 (22) | 0.29 |
| Undetectable IS | 43 (24) | 11 (10) | 32 (45) | < 0.001 |
| DSAm identified | 59 (36) | 29 (30) | 30 (47) | 0.02 |
| Time from last follow-up to rejection, days | ||||
| • Mean ± SD | 107 ± 322 | 58 ± 149 | 184 ± 476 | < 0.001 |
| • Median (IQR) | 42 (10–103) | 21 (6–60) | 91 (47–140) | |
| Time from transplant to rejection, days | ||||
| • Mean ± SD | 1140 ± 3091 | 1052 ± 3809 | 1279 ± 1368 | < 0.001 |
| • Median (IQR) | 396 (103–1251) | 193 (28–953) | 827 (327–1829) | |
| Rejection <30d from transplant | 31 (17) | 28 (25) | 3 (4) | < 0.001 |
| Lymphocyte-depleting agent | ||||
| • Rabbit ATGn | 125 (68) | 66 (59) | 58 (82) | 0.009 |
| • Muromonab | 48 (26) | 39 (35) | 9 (13) | |
| • Alemtuzumab | 7 (4) | 4 (4) | 3 (4) | |
| • Horse ATG | 3 (2) | 2 (2) | 1 (1) | |
| Banff Grade | ||||
| • Banff I (A + B) | 90 (50) | 50 (45) | 40 (56) | 0.18 |
| • Banff II (A + B) | 77 (42) | 53 (48) | 24 (34) | |
| • Banff III | 15 (8) | 8 (7) | 7 (10) | |
| AMRo | 57 (31) | 30 (27) | 27 (38) | 0.12 |
| Percent Interstitial fibrosis | ||||
| • < 5% | 99 (55) | 29 (26) | 25 (35) | 0.005 |
| • 5–25% | 46 (25) | 64 (58) | 24 (34) | |
| • > 25% | 37 (20) | 18 (16) | 22 (31) | |
| Percent Glomerulosclerosis | ||||
| • 0 | 99 (55) | 68 (61) | 31 (43) | 0.02 |
| • 1–20% | 46 (25) | 27 (24) | 19 (27) | |
| • > 20% | 37 (20) | 16 (15) | 21 (30) | |
| Plasma cell or eosinophil-rich | 51 (28) | 24 (22) | 27 (38) | 0.02 |
| Transplant glomerulopathy | 51 (28) | 22 (20) | 29 (41) | 0.003 |
| C4d positivity | 58 (32) | 30 (27) | 28 (39) | 0.08 |
Continuous variables are presented as mean (standard deviation) and categorical variables as N (%) except when noted otherwise
aend-stage renal disease; bhypertension; cdiabetes mellitus; dglomerulonephritis; epolycystic kidney disease; fimmunosuppression; gtacrolimus; hmycophenolate mofetil; icyclosporine; jmammalian target of rapamycin; kserum creatinine; lestimated glomerular filtration rate; mdonor specific antibody; nanti-thymocyte globulin; oantibody-mediated rejection